• 0
Shop Products $

H-PRO-HYP-OH. 1G According to Shigemura et al., Pro-Hyp, a food-derived collagen peptide in human blood, stimulates the growth of fibroblasts from mouse skin. Nakatani et al. observed a chondroprotective effect of the dipeptide in mouse articular cartilage. CAS: 18684-24-7 C10H16N2O4 FW: 228.25

H-PRO-ILE-OH. 1G CAS: 51926-51-3 C11H20N2O3 FW: 228.29

H-PRO-ILE-OH. 5G CAS: 51926-51-3 C11H20N2O3 FW: 228.29

H-PRO-LEU-OH. 5G Substrate for human kidney prolinase (prolyl dipeptidase). CAS: 52899-07-7 C11H20N2O3 FW: 228.29

H-PRO-LYS-OH. 250mg Substrate for prolinase (prolyl dipeptidase). CAS: 71227-70-8 C11H21N3O3 FW: 243.31

H-PRO-LYS-OH. 1G Substrate for prolinase (prolyl dipeptidase). CAS: 71227-70-8 C11H21N3O3 FW: 243.31

H-PRO-MET-OH. 1G Substrate for prolinase (prolyl dipeptidase). CAS: 52899-08-8 C10H18N2O3S FW: 246.33

H-PRO-PHE-OH. 1G Substrate for human kidney prolinase (prolyl dipeptidase).eACE2 inhibitor, ICGG 0.15 mM. CAS: 13589-02-1 C14H18N2O3 FW: 262.31

H-PRO-PHE-OH. 5G Substrate for human kidney prolinase (prolyl dipeptidase).eACE2 inhibitor, ICGG 0.15 mM. CAS: 13589-02-1 C14H18N2O3 FW: 262.31

H-PRO-PRO-OH -HCL. 1G CAS: 76932-06-4 C10H16N2O3 -+ HCl FW: 248.71

H-PRO-PRO-OH -HCL. 5G CAS: 76932-06-4 C10H16N2O3 -+ HCl FW: 248.71

H-PRO-SER-OH. 1G CAS: 71835-80-8 C8H14N2O4 FW: 202.21

H-PRO-TRP-OH. 1G CAS: 35310-39-5 C16H19N3O3 FW: 301.35

H-PRO-TYR-OH. 1G CAS: 19786-36-8 C14H18N2O4 FW: 278.31

H-PRO-VAL-OH. 1G Substrate for human kidney prolinase (prolyl dipeptidase). CAS: 52899-09-9 C10H18N2O3 FW: 214.27

PYR-ALA-OH. 1G Substrate for pyroglutamyl peptidase I. CAS: 21282-08-6 C8H12N2O4 FW: 200.19

PYR-ALA-OH. 5G Substrate for pyroglutamyl peptidase I. CAS: 21282-08-6 C8H12N2O4 FW: 200.19

SAR-GLY-OH. 1G CAS: 38082-72-3 C5H10N2O3 FW: 145.14

H-SER-ALA-OH. 1G CAS: 6403-17-4 C6H12N2O4 FW: 176.17

H-SER-ASP-OH. 250mg CAS: 2543-31-9 C7H12N2O6 FW: 220.18

H-SER-ASP-OH. 1G CAS: 2543-31-9 C7H12N2O6 FW: 220.18

H-SER-GLN-OH. 250mg CAS: 94421-66-6 C8H15N3O5 FW: 233.22

H-SER-GLN-OH. 1G CAS: 94421-66-6 C8H15N3O5 FW: 233.22

H-SER-GLU-OH. 1G CAS: 6403-16-3 C8H14N2O6 FW: 234.21

H-SER-GLY-OH. 1G CAS: 687-63-8 C5H10N2O4 FW: 162.15

H-SER-GLY-OH. 5G CAS: 687-63-8 C5H10N2O4 FW: 162.15

H-SER-HIS-OH. 250mg CAS: 67726-09-4 C9H14N4O4 FW: 242.24

H-SER-HIS-OH. 1G CAS: 67726-09-4 C9H14N4O4 FW: 242.24

H-SER-LEU-OH. 1G Substrate for human kidney dipeptidase. CAS: 6665-16-3 C9H18N2O4 FW: 218.25

H-SER-MET-OH. 1G C8H16N2O4S FW: 236.29

H-SER-PHE-OH. 1G CAS: 16875-28-8 C12H16N2O4 FW: 252.27

H-SER-PHE-OH. 5G CAS: 16875-28-8 C12H16N2O4 FW: 252.27

H-SER-PRO-OH. 250mg This dipeptide is obtained from bradykinin by action of angiotensin-converting enzyme (ACE).eSubstrate for skin fibroblast prolidase. CAS: 23827-93-2 C8H14N2O4 FW: 202.21

H-SER-PRO-OH. 1G This dipeptide is obtained from bradykinin by action of angiotensin-converting enzyme (ACE).eSubstrate for skin fibroblast prolidase. CAS: 23827-93-2 C8H14N2O4 FW: 202.21

H-SER-SER-OH. 250mg CAS: 6620-95-7 C6H12N2O5 FW: 192.17

H-SER-SER-OH. 1G CAS: 6620-95-7 C6H12N2O5 FW: 192.17

H-SER-TYR-OH. 250mg Ser-Tyr stimulated the uptake of deltorphin in SK-N-SH cells.eThe dipeptide forms a complex with Cu(II) acting as a tridentate ligand. CAS: 21435-27-8 C12H16N2O5 FW: 268.27

H-SER-TYR-OH. 1G Ser-Tyr stimulated the uptake of deltorphin in SK-N-SH cells.eThe dipeptide forms a complex with Cu(II) acting as a tridentate ligand. CAS: 21435-27-8 C12H16N2O5 FW: 268.27

H-THR-ALA-OH. 1G CAS: 56217-50-6 C7H14N2O4 FW: 190.2

H-THR-ALA-OH. 5G CAS: 56217-50-6 C7H14N2O4 FW: 190.2

H-THR-ARG-OH. 250mg CAS: 13448-26-5 C10H21N5O4 FW: 275.31

H-THR-ARG-OH. 1G CAS: 13448-26-5 C10H21N5O4 FW: 275.31

H-THR-ASP-OH. 250mg CAS: 108320-97-4 C8H14N2O6 FW: 234.21

H-THR-ASP-OH. 1G CAS: 108320-97-4 C8H14N2O6 FW: 234.21

H-THR-GLN-OH. 250mg CAS: 96337-79-0 C9H17N3O5 FW: 247.25

H-THR-GLN-OH. 1G CAS: 96337-79-0 C9H17N3O5 FW: 247.25

H-THR-GLY-OH. 1G CAS: 686-44-2 C6H12N2O4 FW: 176.17

H-THR-LEU-OH. 1G CAS: 50299-12-2 C10H20N2O4 FW: 232.28

H-THR-MET-OH. 1G CAS: 90729-28-5 C9H18N2O4S FW: 250.32

H-THR-PHE-OH. 1G CAS: 16875-27-7 C13H18N2O4 FW: 266.3

TOS-GLY-PRO-OH. 5G CAS: 100723-71-5 C14H18N2O5S FW: 326.37

H-TRP-ALA-OH. 1G CAS: 24046-71-7 C14H17N3O3 FW: 275.31

H-TRP-ARG-OH -2 HCL. 250mg CAS: 88831-09-8 C17H24N6O3 -+ 2 HCl FW: 433.34

H-TRP-ARG-OH -2 HCL. 1G CAS: 88831-09-8 C17H24N6O3 -+ 2 HCl FW: 433.34

H-TRP-ASN-OH. 250mg CAS: 175027-11-9 C15H18N4O4 FW: 318.33

H-TRP-GLU-OH. 1G Peroxisome proliferator-activated receptor + (PPAR+) antagonist. CAS: 36099-95-3 C16H19N3O5 FW: 333.34

H-TRP-GLY-OH. 1G Trp-Gly was found in the human pituitary gland. Its opioid-like effects in vivo were studied in mice. The monohydrate of the dipeptide forms nanotubes, in which the water is confined. CAS: 7360-09-0 C13H15N3O3 FW: 261.28

H-TRP-LEU-OH. 1G CAS: 13123-35-8 C17H23N3O3 FW: 317.39

H-TRP-MET-OH. 250mg CAS: 21438-63-1 C16H21N3O3S FW: 335.43

H-TRP-PHE-OH. 250mg Forms nanotubes of the Phe-Phe type. CAS: 6686-02-8 C20H21N3O3 FW: 351.41

H-TRP-PHE-OH. 1G Forms nanotubes of the Phe-Phe type. CAS: 6686-02-8 C20H21N3O3 FW: 351.41

H-TRP-SER-OH. 250mg CAS: 133101-40-3 C14H17N3O4 FW: 291.31

H-TRP-SER-OH. 1G CAS: 133101-40-3 C14H17N3O4 FW: 291.31

H-TRP-TRP-OH. 1G CAS: 20696-60-0 C22H22N4O3 FW: 390.44

H-TRP-TRP-OH. 5G CAS: 20696-60-0 C22H22N4O3 FW: 390.44

H-TRP-TYR-OH. 1G CAS: 19653-76-0 C20H21N3O4 FW: 367.41

H-TRP-TYR-OH. 5G CAS: 19653-76-0 C20H21N3O4 FW: 367.41

H-TRP-VAL-OH. 1G CAS: 24613-12-5 C16H21N3O3 FW: 303.36

H-TYR-ALA-OH. 1G CAS: 730-08-5 C12H16N2O4 FW: 252.27

H-TYR-ALA-OH. 5G CAS: 730-08-5 C12H16N2O4 FW: 252.27

H-TYR-GLU-OH. 1G CAS: 2545-89-3 C14H18N2O6 FW: 310.31

H-TYR-GLY-OH. 1G CAS: 673-08-5 C11H14N2O4 FW: 238.24

H-TYR-GLY-OH. 5G CAS: 673-08-5 C11H14N2O4 FW: 238.24

H-TYR-HIS-OH. 250mg Both single-dose administration and repetitive oral application of the dipeptide YH significantly decreased blood pressure in spontaneously hypertensive rats. CAS: 3788-44-1 C15H18N4O4 FW: 318.33

H-TYR-HIS-OH. 1G Both single-dose administration and repetitive oral application of the dipeptide YH significantly decreased blood pressure in spontaneously hypertensive rats. CAS: 3788-44-1 C15H18N4O4 FW: 318.33

H-TYR-ILE-OH. 1G CAS: 40829-32-1 C15H22N2O4 FW: 294.35

H-TYR-LEU-OH. 1G A dipeptide from +-lactoglobulin showing ACE-inhibitory activity, ICGG 122.1 ++mol. CAS: 17355-10-1 C15H22N2O4 FW: 294.35

H-TYR-LEU-OH. 5G A dipeptide from +-lactoglobulin showing ACE-inhibitory activity, ICGG 122.1 ++mol. CAS: 17355-10-1 C15H22N2O4 FW: 294.35

H-TYR-LYS-OH. 1G Reaction of the dipeptide KY with diethylenetriaminepentaacetic (DTPA) cyclic anhydride yielded monovalent and bivalent haptens. In vitro, the antibody conjug ate (which was prepared by coupling F(abG)2 or FabG fragments of an antibody specific for the human high molecular weight melanoma associated antigen to FabG fragments of an antibody specific for In-DTPA complexes) mediated binding of the ---In-labeled haptens to melanoma cells. In vivo, it allowed specific localization of the haptens in A375 tumors. The bivalent hapten exhibited much higher efficiency at targeting ---In onto cells, both in vitro and in vivo. CAS: 54925-88-1 C15H23N3O4 FW: 309.37

H-TYR-LYS-OH. 5G Reaction of the dipeptide KY with diethylenetriaminepentaacetic (DTPA) cyclic anhydride yielded monovalent and bivalent haptens. In vitro, the antibody conjug ate (which was prepared by coupling F(abG)2 or FabG fragments of an antibody specific for the human high molecular weight melanoma associated antigen to FabG fragments of an antibody specific for In-DTPA complexes) mediated binding of the ---In-labeled haptens to melanoma cells. In vivo, it allowed specific localization of the haptens in A375 tumors. The bivalent hapten exhibited much higher efficiency at targeting ---In onto cells, both in vitro and in vivo. CAS: 54925-88-1 C15H23N3O4 FW: 309.37

H-TYR-PHE-OH. 1G CAS: 17355-11-2 C18H20N2O4 FW: 328.37

H-TYR-PHE-OH. 5G CAS: 17355-11-2 C18H20N2O4 FW: 328.37

H-TYR-TRP-OH. 250mg CAS: 60815-41-0 C20H21N3O4 FW: 367.41

H-TYR-TYR-OH. 1G Narai-Kanayama and Aso showed that Tyr-Tyr and Tyr-Tyr-Tyr (H-5230) efficiently inhibit angiotensin I-converting enzyme (ACE) from rabbit lung, their ICGG values were 34 ++M and 51 ++M, respectively. These two tyrosine peptides exhibited a mix of competitive and noncompetitive inhibitions. CAS: 1050-28-8 C18H20N2O5 FW: 344.37

H-TYR-VAL-OH. 1G CAS: 17355-09-8 C14H20N2O4 FW: 280.32

H-TYR-VAL-OH. 5G CAS: 17355-09-8 C14H20N2O4 FW: 280.32

H-VAL-ALA-OH. 1G A hydrophobic nanotube-forming dipeptide. The pores absorb and store gases as methane or hydrogen. CAS: 27493-61-4 C8H16N2O3 FW: 188.23

H-VAL-ALA-OH. 5G A hydrophobic nanotube-forming dipeptide. The pores absorb and store gases as methane or hydrogen. CAS: 27493-61-4 C8H16N2O3 FW: 188.23

H-VAL-ASP-OH. 1G CAS: 20556-16-5 C9H16N2O5 FW: 232.24

H-VAL-GLU-OH. 1G C10H18N2O5 FW: 246.26

H-VAL-GLY-OH. 1G CAS: 686-43-1 C7H14N2O3 FW: 174.2

H-VAL-GLY-OH. 5G CAS: 686-43-1 C7H14N2O3 FW: 174.2

H-VAL-HIS-OH. 1G Corresponds to the N-terminus of the +-chain of hemoglobin A which reacts with blood glucose yielding hemoglobin A1c. CAS: 13589-07-6 C11H18N4O3 FW: 254.29

H-VAL-HIS-OH. 5G Corresponds to the N-terminus of the +-chain of hemoglobin A which reacts with blood glucose yielding hemoglobin A1c. CAS: 13589-07-6 C11H18N4O3 FW: 254.29

H-VAL-ILE-OH. 1G A hydrophobic, nanotube-forming dipeptide. CAS: 20556-14-3 C11H22N2O3 FW: 230.31

H-VAL-LEU-OH -HCL. 5G Substrate for human kidney dipeptidase. CAS: 95977-55-2 C11H22N2O3 -+ HCl FW: 266.77

H-VAL-MET-OH. 1G CAS: 14486-09-0 C10H20N2O3S FW: 248.35

H-VAL-PHE-OH. 1G VF inhibited angiotensin-1 converting enzyme (ACE), ICGG 9.2 ++M.eContrary to H-Ile-Phe-OH (G-2420) containing merely an additional methyl group, this dipeptide does not self-assemble. CAS: 3918-92-1 C14H20N2O3 FW: 264.32

H-VAL-PRO-OH -HCL. 1G Substrate for skin fibroblast prolidase. CAS: 105931-64-4 C10H18N2O3 -+ HCl FW: 250.73

H-VAL-SER-OH. 250mg Forms nanotubes in the presence of trifluoroethanol. CAS: 13588-94-8 C8H16N2O4 FW: 204.23

Category